Exchange: NASDAQ·Updated 07:30 PM EDT

NVCR News

News
all
press releases
Novocure Announces Upcoming Investor Events
Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. Wells Fargo 21st Annual Healthcare Conference, September 9, 2026: Frank Leonard, Chief Executive Officer, will take part in a fireside chat at 10:15 a.m. ET, as well as one-on-one meetings with...
Business Wire
More News
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice
Does NovoCure (NVCR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
4 Healthcare Stocks to Watch as Defensive Demand Strengthens
Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.
Zacks
NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?
NovoCure (NVCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade
The mean of analysts' price targets for NovoCure (NVCR) points to a 46.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Unlocking NovoCure (NVCR) International Revenues: Trends, Surprises, and Prospects
Examine the evolution of NovoCure's (NVCR) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Zacks
Why Did CSX, UNP, NVCR Stocks Surge To 52-Week Highs Today?
Investors rewarded strong execution, improving profits and raised outlook.
Stocktwits
NVCR Stock Surges 28% For Best Day In Over 1.5 Years — What’s Driving The Rally?
The medical device maker, which develops Tumor Treating Fields (TTFields) therapy for cancer, said Q2 marked its strongest performance to date.
Stocktwits

Advertisement|Remove ads.